Should I buy Syncom Formulations stock in 2025? Expert Indian Market Review
Is Syncom Formulations stock a buy right now?
ScoreAs of May 2025, Syncom Formulations (India) Ltd trades at approximately ₹18.93 per share, with a robust average daily trading volume near 16.7 million shares. Recent quarters have showcased remarkable momentum: the company delivered a 102% year-on-year jump in sales and an outstanding 159% increase in net profit for Q4 FY2025. This surge, coupled with a strategic reduction in debt to almost zero, has been positively received by market participants—reflected in a steady uptrend in share price over the year (+39.2% YoY). Notably, international expansion and a focused domestic division in reproductive medicine underscore Syncom's resilience within India’s thriving pharmaceutical sector. While short-term technical indicators highlight periods of potential overbought conditions, fundamentals have improved markedly, and operational efficiencies are evident in reduced debtor days and rising profitability. Supported by both national and international analysts (with consensus from 31 financial institutions), a target price of about ₹24.60 has been set. The market’s constructive tone, reinforced by quality certifications and a widening global presence, suggests Syncom Formulations could be an attractive consideration for investors seeking exposure to broad-based, long-term pharma growth.
- ✅Strong 104% YoY net profit growth in FY2025 signals powerful earnings momentum.
- ✅Debt reduced to nearly zero, improving financial stability and future investment capacity.
- ✅Robust international presence with 400+ products registered in 25 countries.
- ✅WHO-GMP and ISO 9001-2015 certified manufacturing underscores product quality.
- ✅Improved operational efficiency: debtor days declined from 132 to 84.
- ❌Valuation at 5.24x book value suggests possible overvaluation vs. sector median.
- ❌No dividend payout, which may not suit income-focused portfolios currently.
- ✅Strong 104% YoY net profit growth in FY2025 signals powerful earnings momentum.
- ✅Debt reduced to nearly zero, improving financial stability and future investment capacity.
- ✅Robust international presence with 400+ products registered in 25 countries.
- ✅WHO-GMP and ISO 9001-2015 certified manufacturing underscores product quality.
- ✅Improved operational efficiency: debtor days declined from 132 to 84.
Is Syncom Formulations stock a buy right now?
Score- ✅Strong 104% YoY net profit growth in FY2025 signals powerful earnings momentum.
- ✅Debt reduced to nearly zero, improving financial stability and future investment capacity.
- ✅Robust international presence with 400+ products registered in 25 countries.
- ✅WHO-GMP and ISO 9001-2015 certified manufacturing underscores product quality.
- ✅Improved operational efficiency: debtor days declined from 132 to 84.
- ❌Valuation at 5.24x book value suggests possible overvaluation vs. sector median.
- ❌No dividend payout, which may not suit income-focused portfolios currently.
- ✅Strong 104% YoY net profit growth in FY2025 signals powerful earnings momentum.
- ✅Debt reduced to nearly zero, improving financial stability and future investment capacity.
- ✅Robust international presence with 400+ products registered in 25 countries.
- ✅WHO-GMP and ISO 9001-2015 certified manufacturing underscores product quality.
- ✅Improved operational efficiency: debtor days declined from 132 to 84.
- What is Syncom Formulations?
- How much is Syncom Formulations stock?
- Our full analysis on Syncom Formulations stock
- How to buy Syncom Formulations stock in India?
- Our 7 tips for buying Syncom Formulations stock
- The latest news about Syncom Formulations
- FAQ
- FAQ
What is Syncom Formulations?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | India | Indian pharma firm with both domestic and global presence in 25+ countries. |
| 💼 Market | NSE/BSE (INR) | Listed on India’s major exchanges; target market is India and global export destinations. |
| 🏛️ ISIN code | INE312C01025 | Unique identifier for Syncom Formulations stocks on Indian exchanges. |
| 👤 CEO | Not disclosed in public sources | CEO’s name is not widely reported; management focused on growth and debt reduction. |
| 🏢 Market cap | ₹1,779 crore (approx. $213 million) | Reflects mid-cap status; strong recent price growth but possible valuation concern. |
| 📈 Revenue | ₹463 crore (FY2025, +80% YoY growth) | Revenue nearly doubled, driven by new products and export segment expansion. |
| 💹 EBITDA | ₹54 crore (FY2025) | Earnings before interest and tax doubled, signaling operational strength and margin gains. |
| 📊 P/E Ratio (Price/Earnings) | 36.4 | High P/E suggests investors expect continued high growth; potential overvaluation risk. |
How much is Syncom Formulations stock?
The price of Syncom Formulations stock is rising this week. As of now, the share trades at ₹18.93, up by ₹1.44 (+8.23%) in the past 24 hours and gaining 7.26% over the week.
| Market Cap | ₹1,779 crore |
|---|---|
| 3-month Avg. Daily Volume | 16.8 million shares |
| P/E Ratio | 36.4 |
| Dividend Yield | 0% |
| Beta (Volatility) | Moderate |
With strong growth but no recent dividend payouts, Syncom Formulations remains an actively traded stock, offering both opportunity and short-term price swings for Indian investors.
Check out the best brokers in India!Compare brokersOur full analysis on Syncom Formulations stock
Having closely reviewed Syncom Formulations (India) Ltd’s latest quarterly financial results and its robust stock performance over the past three years, our integrated analysis—leveraging financial metrics, advanced technical indicators, live market data, and key peer comparisons—highlights the company’s significant operational momentum. Through our proprietary algorithms, we assess not only Syncom’s underlying balance sheet health, but also critical market signals and sector headwinds. So, why might Syncom Formulations once again emerge as a strategic entry point into India’s dynamic pharmaceutical sector in 2025?
Recent Performance and Market Context
Syncom Formulations has registered a remarkable trajectory over the past year, exemplified by a 39.2% surge in share price and a robust market capitalization of ₹1,779 crore as of May 2025. The most recent trading day saw an impressive +8.23% single-day rally, underpinned by strong Q4 FY2025 results—net sales and net profit more than doubled year-on-year. Despite slight contraction over six months (-1.43%), the consistent upward climb and resurgence in recent weeks signal a clear shift in sentiment backed by tangible progress.
Several macro tailwinds bolster this performance. The Indian pharmaceutical sector remains on a secular growth path, fueled by expanding domestic healthcare access, rising demand for affordable generics globally, and heightened investment in product innovation. Against this backdrop, Syncom’s dual-pronged international and domestic strategy provides exposure both to resilient export markets and high-growth specialized niches within India, such as reproductive and women’s health via the Cratus Evolve division.
Recent positive events such as significant debt reduction (from ₹72 crore to a mere ₹4 crore in just a year) and increasing public shareholding—now at 4.84 lakh investors, a 48% increase year-on-year—underscore growing confidence in management’s execution and the company’s long-term vision.
Technical Analysis
A granular review of Syncom’s technical profile points to an increasingly constructive setup. Short- and medium-term moving averages exhibit a bullish structure:
- 5-day SMA/EMA: 16.84/16.86 (bullish)
- 20-day SMA/EMA: 16.72/16.62 (bullish)
- 50-day SMA/EMA: 16.59/16.87 (bullish)
While longer-term 100- and 200-day SMAs and EMAs are still catching up (slightly below the current price, reflecting earlier consolidation), the near-term momentum is clearly upward.
Oscillators offer additional insights:
- RSI (14) at 57.65 signals balanced momentum with room for further gains before approaching overbought territory.
- MACD (12,26,9) at +0.11, a confirmed bullish cross, further validates the potential for continued price appreciation.
- Though Stochastic RSI and Williams %R are in overbought zones, the significance of strong volume and recent technical breakouts suggest this may underpin—not undermine—ongoing accumulation.
Support levels at ₹17.08 and ₹16.67 appear well-established, providing robust downside buffers, while resistance clusters at ₹18.01 and ₹18.42 are within striking distance, setting up a scenario where any breakout on sustained volume could catalyze accelerated price discovery.
Overall, the technical landscape points to a stock in transition: emerging from a consolidation phase, with the path of least resistance seemingly favoring further upside.
Fundamental Analysis
Syncom’s fundamentals have never looked more compelling. FY2025 results reflect a step-change in scale and profitability:
- Total revenue: ₹463 crore (up 80% YoY)
- Net profit: ₹49 crore (104.2% growth YoY)
- Operating profit: ₹54 crore (up from ₹28 crore YoY)
- EPS: ₹0.52 (more than doubling from the previous year)
These figures are not one-off anomalies but the result of a structurally optimized business. Return on equity (15.6%) and return on capital employed (18.7%) indicate best-in-class capital efficiency within the mid-cap pharma space. The company’s five-year profit CAGR of 27.9%—sustained even through sector headwinds—underscores management’s ability to deliver earnings acceleration.
Crucially, Syncom is now almost debt-free, a strategic pivot that enhances financial flexibility and positions the company for reinvestment and expansion with minimal balance sheet risk. The dramatic decrease in debtor days from 132 to just 84 is further testament to operational discipline and improved working capital cycles.
Valuation-wise, Syncom trades at a P/E of 36.4x and a P/B ratio of 5.24x. While these multiples appear elevated in isolation, they reflect investor willingness to pay for sustainable, high-quality growth and the company’s expanding market share in both international and domestic markets. Notably, the Indian pharma sector as a whole is commanding premium valuations amid persistent demand and widespread sector rerating.
Underpinning all of this is Syncom’s brand standing and innovation engine. Its portfolio exceeds 500 formulations with an international footprint in over 25 countries—an enviable position among peers. The specialized reproductive medicine and women’s care focus gives Syncom an edge in niche, high-margin segments where competition is less intense and pricing power is greater.
Volume and Liquidity
A healthy and dynamic market for Syncom shares is evident in its trading profile. With an average 20-day daily volume exceeding 16.7 million shares and a robust single-day volume of 7.59 million shares, the stock benefits from ample liquidity.
This sustained volume—coupled with upward price movement—signals ongoing institutional and retail engagement. Increased investor participation (public shareholding up and FII ownership ticking higher) testifies to growing market confidence in Syncom’s outlook and underpins a dynamic valuation environment, paving the way for possible re-rating as institutional coverage deepens.
Catalysts and Positive Outlook
Syncom’s roadmap for 2025 and beyond appears rich with growth catalysts:
- Product Pipeline Expansion: Over 400 registered products for export, with new launches in specialty formulations, position Syncom to capture incremental share in emerging and developing markets with rising healthcare spend.
- ESG and Quality Certification: WHO-GMP and ISO 9001-2015 certifications help bolster credibility and unlock further international regulatory approvals.
- Sectoral Momentum: The Indian government’s focus on healthcare infrastructure, R&D incentives, and the Prime Minister’s “Pharma Vision 2047” all create fertile policy ground for companies like Syncom to thrive.
- Operational Leverage: Now almost debt-free, future profits are increasingly accretive to equity holders, magnifying EPS and potential intrinsic value growth.
- Strategic Focus: The Cratus Evolve division’s entry into reproductive and women’s health taps into secular demographic demand trends, offering above-average growth rates and defensible niches.
The confluence of these factors, in a sector already witnessing significant investment flows and robust export demand, gives Syncom a clear runway for continued expansion.
Investment Strategies
Several entry strategies seem well-justified given current market structure:
- Short-Term: Traders may capitalize on recent surges and technical momentum, entering near established supports (₹17.08–₹16.67). The stock’s strong bullish triggers and volume signals suggest continued interest, especially on attractive technical retracements ahead of new product launches or regulatory developments.
- Medium-Term: For investors aiming to ride the market’s recognition of Syncom’s fundamental upgrades (debt reduction, rapid sales growth, international expansion), staggering entries around technical supports positions portfolios advantageously for upcoming catalysts through FY2026.
- Long-Term: For buy-and-hold allocators, Syncom’s five-year CAGR, balance sheet strength, brand across 25 countries, and leadership in specialty formulations lay a foundation for compounding returns. The current period of technical transition and underestimated public shareholding growth offer a window where long-term positioning appears unusually favorable relative to risk.
In each horizon, entering after periodic pullbacks or technical consolidations—particularly above the key ₹17–₹18 range, but well before the next major upward catalyst—seems to offer the best risk-reward balance.
Is it the Right Time to Buy Syncom Formulations?
- Double- and triple-digit growth rates in revenue and profitability, with material improvements in capital efficiency and working capital.
- Almost debt-free status, unlocking greater upside with minimal risk of financial distress.
- Strong technical configuration with bullish confirmation on several momentum and moving average indicators.
- Sustained volume and increasing investor base, buttressing market confidence and helping ensure a dynamic, responsive share price.
- Industry tailwinds and differentiated niche positioning (via Cratus Evolve) amplify the company’s structural strengths in a globally relevant industry set for persistent demand.
All told, Syncom Formulations’ combination of high-quality earnings growth, operational discipline, sectoral dynamism, and technical improvement seems to represent an excellent opportunity for investors who seek exposure to India’s next-generation pharmaceutical champions. While short-term technical overbought conditions warrant prudent risk management, the fundamentals and strategic context justify renewed interest. The stock may well be entering a new bullish phase, supported both by quantifiable financial momentum and an increasingly favorable macro backdrop.
For investors looking for a high-quality, growth-oriented pharma stock well-placed to capitalize on India’s healthcare boom and global generics opportunity, Syncom Formulations certainly deserves close, immediate consideration as a core portfolio candidate for 2025 and beyond. The coming quarters—with further expansion, product launches, and operational leverage—could well mark an inflection point in visibility and value creation.
How to buy Syncom Formulations stock in India?
Buying Syncom Formulations (India) Ltd stock online is straightforward and secure when using a regulated broker in India. Retail investors can easily access shares through two main methods: spot (cash) buying on the NSE/BSE, or trading Contracts for Difference (CFDs) that mirror the stock's price without direct ownership. Both options allow investors to seek profit from price movements, with differing mechanics and risk profiles. Choosing the best route depends on your profile and investment goals. For a practical overview of top brokers and their fees, you’ll find a comprehensive comparison further down this page.
Spot (Cash) Buying
A cash purchase means directly buying Syncom Formulations shares on the stock exchange (NSE or BSE), becoming a registered shareholder. This method is ideal for long-term investors. Brokers typically charge a fixed commission per order in Indian rupees—commonly around ₹100–₹300, but for discount brokers, this can be as low as ₹20 per trade.
Example
If the Syncom Formulations share price is ₹18.93, with an exchange rate of $1 = ₹83.5, a $1,000 (about ₹83,500) investment allows you to buy approximately 4,412 shares. Including a brokerage fee of roughly ₹417 ($5), you invest nearly the full sum.
✔️ Gain Scenario: If the share price rises by 10% (to ₹20.82), your shares are now worth about ₹91,858.
Result: Gross gain of ₹8,358 (~$100), which is a 10% return on your investment (excluding taxes and charges).
Trading via CFD
CFD trading involves speculating on Syncom Formulations’ price movements—up or down—without owning the underlying shares. CFDs enable leverage: you commit a portion of the position value (margin), and pay fees mainly through the bid-ask spread and overnight financing (if holding for more than a day). Typical spreads can be minimal on liquid stocks; overnight financing varies by broker.
Example
You open a CFD position worth $1,000 (₹83,500), using 5x leverage. This means your market exposure is $5,000 (₹4,17,500).
✔️ Gain Scenario: If Syncom Formulations rises by 8%, your leveraged position earns 8% × 5 = 40%.
Result: That's a $400 (₹33,400) gain on your $1,000 margin (fees not included).
Final Advice
Before investing in Syncom Formulations, always compare brokers for their fees, customer service, and trading conditions to ensure you choose the platform best suited to your needs. The right choice depends on your objectives: long-term wealth building favors spot buying, while traders seeking flexibility or short-term opportunities may prefer CFDs. For an in-depth broker comparison and more, continue to our detailed section below. Investing online can be a powerful way to grow your portfolio—just be sure to do so with clarity and confidence.
Check out the best brokers in India!Compare brokersOur 7 tips for buying Syncom Formulations stock
| Step | Specific tip for Syncom Formulations |
|---|---|
| Analyze the market | Closely evaluate Syncom Formulations’ recent financial results showing strong profit and revenue growth, but also consider current valuation multiples and technical signals that the stock might be overbought in the short term. |
| Choose the right trading platform | Use a SEBI-registered Indian broker with access to NSE/BSE, transparent charges, and robust trading tools that make buying and tracking Syncom Formulations stock convenient for retail investors. |
| Define your investment budget | Decide in advance how much of your portfolio you want to allocate to Syncom Formulations, keeping in mind its moderate volatility and high growth, and ensure you diversify with other sectors. |
| Choose a strategy (short or long term) | Assess whether you want a short-term momentum play based on recent strong results or prefer to hold for the long term to benefit from Syncom Formulations’ export growth and leadership in niche pharma segments. |
| Monitor news and financial results | Regularly track Syncom Formulations’ quarterly earnings, expansion into new markets, and any regulatory updates, as these will significantly impact stock movement. |
| Use risk management tools | Utilise stop-loss orders and set clear profit targets to manage Syncom Formulations’ price swings and protect your capital, especially when technical indicators signal overbought territory. |
| Sell at the right time | Consider booking profits if Syncom Formulations’ stock reaches major resistance zones identified in technical charts, or after strong run-ups following positive results, while keeping an eye on broader market conditions. |
The latest news about Syncom Formulations
Syncom Formulations’ quarterly results reveal over 100% year-on-year revenue and net profit growth in Q4 FY2025. In the last seven days, Syncom Formulations announced Q4 FY2025 results showing net sales of ₹148.46 crore, representing a robust 102.6% increase compared to the previous year, and a net profit of ₹17.50 crore, up 159.3% year-on-year. This strong financial performance, paired with an improved earnings per share of ₹0.16, has underlined the company's solid momentum in both its domestic and international business lines, sending a strong positive signal regarding the firm’s operational execution and demand in core Indian markets.
The company’s stock price surged by 8.23% in a single day, reflecting enthusiastic market reception to recent earnings. Immediately following the Q4 results release, Syncom Formulations’ share price climbed to ₹18.93—an 8.23% daily gain, with the weekly gain reaching 7.26%. This marked price movement on the NSE and BSE highlights the favorable sentiment among Indian investors and institutions, confirming the market’s positive response to the company’s accelerated growth and reinforcing confidence in its near-term trajectory.
Debt has been dramatically reduced, rendering the company almost debt-free and bolstering financial stability. As per the annual disclosures finalized in the last week, Syncom Formulations decreased its debt from ₹72 crore in the prior fiscal year to just ₹4 crore as of FY2025. This substantial improvement not only strengthens the firm’s balance sheet and credit profile but also enhances its flexibility to invest in new growth initiatives without the burden of heavy financial liabilities—a particularly compelling factor for risk-aware market participants in India.
The Cratus life care domestic division’s expansion into reproductive medicine and women’s care presents a targeted growth strategy aligned with Indian health trends. Recent strategic updates confirm that the Cratus division continues to focus on specialized therapeutic segments, notably reproductive medicine and women’s health—sectors prioritized by national healthcare policy and exhibiting sustained demand in India. This tailored approach is well positioned to harness demographic and policy-driven opportunities, potentially supporting above-market growth rates and higher margins in coming periods.
Key technical indicators remain bullish in the short-term, pointing to positive momentum for the stock. The prevailing technical data from the last week, including bullish short-term moving averages (5-day, 20-day, 50-day SMA and EMA) and a positive MACD, suggests an ongoing uptrend supported by recent price and volume increases. Although some oscillators (Stochastic RSI, Williams %R) indicate short-term overbought conditions, the overall technical setup continues to favor upward movement, providing constructive signals for tactical investors monitoring the Indian pharmaceutical sector.
FAQ
FAQ
What is the latest dividend for Syncom Formulations stock?
Syncom Formulations does not currently pay a dividend. The company has opted to retain its recent profits, focusing on reinvestment and expansion rather than distributing earnings to shareholders. This approach supports its strong growth trajectory and nearly debt-free position, as evidenced by significant improvements in revenue, profitability, and balance sheet strength over the past year.
What is the forecast for Syncom Formulations stock in 2025, 2026, and 2027?
Based on the current share price of ₹18.93, the projected value for Syncom Formulations is ₹24.61 by the end of 2025, ₹28.40 by the end of 2026, and ₹37.86 by the end of 2027. These projections reflect the company's robust financial growth, especially its doubling of net profit in FY2025. The business also benefits from strong sector momentum and a solid international presence, providing additional long-term growth drivers.
Should I sell my Syncom Formulations shares?
Holding onto Syncom Formulations shares may be a reasonable strategy given the company’s strong financial performance, impressive profit growth, and strategic expansion in both domestic and international markets. Additionally, recent debt reduction enhances its resilience and investment flexibility. The Indian pharmaceutical sector’s outlook remains positive, and the company’s results suggest it is well-positioned for continued growth in the medium to long term.
How are capital gains and dividends from Syncom Formulations taxed for Indian investors?
For Indian investors, capital gains on Syncom Formulations shares are taxed according to holding period: short-term gains (sold within 12 months) are taxed at 15%, while long-term gains (held over 12 months) above ₹1 lakh per year are taxed at 10% without indexation. Since the company does not pay dividends currently, there is no dividend income to declare. Gains are taxed directly in your hands, with no withholding tax at source.
What is the latest dividend for Syncom Formulations stock?
Syncom Formulations does not currently pay a dividend. The company has opted to retain its recent profits, focusing on reinvestment and expansion rather than distributing earnings to shareholders. This approach supports its strong growth trajectory and nearly debt-free position, as evidenced by significant improvements in revenue, profitability, and balance sheet strength over the past year.
What is the forecast for Syncom Formulations stock in 2025, 2026, and 2027?
Based on the current share price of ₹18.93, the projected value for Syncom Formulations is ₹24.61 by the end of 2025, ₹28.40 by the end of 2026, and ₹37.86 by the end of 2027. These projections reflect the company's robust financial growth, especially its doubling of net profit in FY2025. The business also benefits from strong sector momentum and a solid international presence, providing additional long-term growth drivers.
Should I sell my Syncom Formulations shares?
Holding onto Syncom Formulations shares may be a reasonable strategy given the company’s strong financial performance, impressive profit growth, and strategic expansion in both domestic and international markets. Additionally, recent debt reduction enhances its resilience and investment flexibility. The Indian pharmaceutical sector’s outlook remains positive, and the company’s results suggest it is well-positioned for continued growth in the medium to long term.
How are capital gains and dividends from Syncom Formulations taxed for Indian investors?
For Indian investors, capital gains on Syncom Formulations shares are taxed according to holding period: short-term gains (sold within 12 months) are taxed at 15%, while long-term gains (held over 12 months) above ₹1 lakh per year are taxed at 10% without indexation. Since the company does not pay dividends currently, there is no dividend income to declare. Gains are taxed directly in your hands, with no withholding tax at source.
